|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project.
|
21347282 |
2011 |
|
Bacterial Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings indicate that NLRC5 is dispensable for cytokine induction in virus and bacterial infections under physiologic conditions.
|
21148033 |
2011 |
|
Rhinovirus infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, using virus deletion mutants and silencing for nucleotide-binding oligomerization domain-like receptors (NLRs), we show that the rhinovirus ion channel protein 2B triggers NLRP3 and NLRC5 inflammasome activation and IL-1β secretion in bronchial cells.
|
23815151 |
2013 |
|
Respiratory Syncytial Virus Infections
|
0.010 |
AlteredExpression
|
group |
BEFREE |
A model is therefore proposed in which the host upregulates MHC-I expression during RSV infection directly via the induction of RIG-I and NLRC5 expression.
|
25972545 |
2015 |
|
Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RSV infection of A549 cells promotes upregulation of NLRC5 via beta interferon (IFN-β) production, since the NLRC5-inducing activity in a conditioned medium from RSV-infected A549 cells was removed by antibody to IFN-β, but not by antibody to IFN-γ.
|
25972545 |
2015 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Role of NLRC5 in progression and reversal of hepatic fibrosis.
|
26806094 |
2016 |
|
Lymphocyte Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
|
27162338 |
2016 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
|
27162338 |
2016 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Thus, our findings suggest that NLRC5 may play an important role in progression of HCC and provide a potential therapeutic value in this tumor.
|
26975630 |
2016 |
|
Fibrosis, Liver
|
0.040 |
Biomarker
|
disease |
BEFREE |
NLRC5, as the largest member of nucleotide-binding domain and leucine-rich repeat (NLRs) family, has recently been implicated in the development of hepatic fibrosis.
|
27525969 |
2016 |
|
Fibrosis, Liver
|
0.040 |
Biomarker
|
disease |
BEFREE |
NLRC5 inhibition would be a promising therapeutic avenue for treating hepatic fibrosis.
|
26592197 |
2016 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, overexpression of NLRC5 promoted the proliferation, migration and invasion of HCC cells in vitro.
|
26975630 |
2016 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, our findings suggest that NLRC5 may play an important role in progression of HCC and provide a potential therapeutic value in this tumor.
|
26975630 |
2016 |
|
Keloid
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, herein, we investigated the effects of NLRC5 on keloid fibroblasts (KFs) and transforming growth factor-β1 (TGF-β1)-induced collagen expression and explored the underlying mechanism.
|
27525969 |
2016 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we review the role of NLRC5 in cancer immune evasion and the future prospects for cancer research.
|
28718425 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Better awareness of the multiple roles of NLRC5 will help to define its overall contribution to immune responses and cancer.
|
28261210 |
2017 |
|
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Given the importance of CD8<sup>+</sup> T and NK cells in controlling infection and cancer, it is not surprising that NLRC5 is also starting to emerge as a central player in these diseases.
|
28215281 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we review the role of NLRC5 in cancer immune evasion and the future prospects for cancer research.
|
28718425 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Better awareness of the multiple roles of NLRC5 will help to define its overall contribution to immune responses and cancer.
|
28261210 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Given the importance of CD8<sup>+</sup> T and NK cells in controlling infection and cancer, it is not surprising that NLRC5 is also starting to emerge as a central player in these diseases.
|
28215281 |
2017 |
|
Fibrosis, Liver
|
0.040 |
Biomarker
|
disease |
BEFREE |
As the largest member of the nucleotide‑binding domain and leucine‑rich repeat (NLR) family, NLRC5 has been shown to be pivotal in the development of hepatic fibrosis.
|
28713900 |
2017 |
|
Virus Diseases
|
0.030 |
AlteredExpression
|
group |
BEFREE |
When the modulation of NLRC5 in pathogen infection was analyzed, it was found that zebrafish NLRC5 was upregulated by both bacterial and viral infection.
|
27876605 |
2017 |
|
Virus Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Therefore, our study highlights how NLRC5 regulates multiple immune effector mechanisms to promote the host defense during influenza virus infection.
|
28615208 |
2017 |